Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.37 |
| ▸ | GFER | P55789 | 4/20 | 0.37 |
| ▸ | S100A4 | P26447 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | ALPI | P09923 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3444768 | 0.84 | ALDH1A1 (0.36) | MEN1KMT2AGFERPOLBTDP1 | |
| SCHEMBL4839201 | 0.84 | MAPT (0.39) | MEN1KMT2APOLBL3MBTL1TDP1 | |
| SCHEMBL8057951 | 0.84 | MEN1 (0.35) | MEN1KMT2AGFERS100A4GPR35 | |
| SCHEMBL9466058 | 0.81 | TDP1 (0.34) | MEN1KMT2AGFERGPR35TDP1 | |
| SCHEMBL12647913 | 0.80 | MEN1 (0.35) | MEN1KMT2AGFERS100A4GPR35 | |
| SCHEMBL596867 | 0.80 | TDP1 (0.38) | MEN1KMT2AGFERS100A4GPR35 | |
| SCHEMBL6480654 | 0.80 | TDP1 (0.40) | MEN1KMT2AGFERS100A4GPR35 | |
| SCHEMBL27833949 | 0.80 | TDP1 (0.33) | MEN1KMT2AGFERGPR35TDP1 | |
| SCHEMBL3107389 | 0.80 | MAPT (0.48) | MEN1KMT2AGFERPOLBL3MBTL1 | |
| SCHEMBL15206820 | 0.80 | MEN1 (0.35) | MEN1KMT2AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011545-A1 | Chemical Compounds - 759 | ASTRAZENECA AB (SE) | 2015-01-08 | — | — | US | disclosed |
| US-20140170110-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES | ALMIRALL, S.A. (ES) | 2014-06-19 | — | — | US | disclosed |
| US-20140155394-A1 | Chemical Compounds - 759 | ASTRAZENECA AB (SE) | 2014-06-05 | — | — | US | disclosed |
| CN-103649085-A | Pyridin-2(1h)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases | ALMIRALL SA | 2014-03-19 | — | — | CN | disclosed |
| US-8486966-B2 | 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer | ASTRAZENECA AB (SE) | 2013-07-16 | — | — | US | disclosed |
| WO-2012160030-A1 | PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES | ALMIRALL, S.A. (ES) | 2012-11-29 | — | — | WO | disclosed |
| US-20100324040-A1 | 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2010-12-23 | — | — | US | disclosed |
| CN-101679426-A | 9- (pyrazol-3-yl) -9H-purin-2-amine and 3- (pyrazol-3-yl) -3H-imidazo [4, 5-b ] pyridin-5-amine derivatives and their use to treat cancer | ASTRAZENECA AB | 2010-03-24 | — | — | CN | disclosed |
| EP-2152705-A1 | 9- (PYRAZOL- 3 -YL) - 9H- PURINE-2 -AMINE AND 3- (PYRAZ0L-3-YL) -3H-IMIDAZ0 [4, 5-B]PYRIDIN-5-AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008135785-A1 | 9- (PYRAZOL- 3 -YL) - 9H- PURINE-2 -AMINE AND 3- (PYRAZ0L-3-YL) -3H-IMIDAZ0 [4, 5-B] PYRIDIN-5-AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| US-4430495-A | Process for preparing lincomycin and clindamycin ribonucleotides | THE UPJOHN COMPANY (US) | 1984-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140170110-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES | JAK1, JAK3, JAK2 | MEN1 1355/4885KMT2A 1168/4885GFER 3079/4885 |
| US-20150011545-A1 | Chemical Compounds - 759 | MCL1, BCL9, BCL9L | MEN1 229/4885KMT2A 923/4885GFER 3500/4885 |
| US-20140155394-A1 | Chemical Compounds - 759 | MCL1, BCL9, BCL9L | MEN1 229/4885KMT2A 923/4885GFER 3500/4885 |
| US-20100324040-A1 | 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | THPO, MPL, MCL1 | MEN1 1553/4885KMT2A 924/4885GFER 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.